Skip to main content
. Author manuscript; available in PMC: 2006 Jan 27.
Published in final edited form as: Nat Med. 2005 Apr 24;11(5):491–498. doi: 10.1038/nm1238

Figure 1. Lung ceramide levels are increased by VEGFR blockade.

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

Figure 1

(a) Mouse lung ceramide levels induced by VEGFR inhibitor (VEGFR-inh, SU5416) or vehicle (Ctl); n=4 mice/group; mean +SD. *p=0.01. Mouse lung ceramide expression (brown, arrows) at 3d after treatment (a, alveoli, b, bronchial epithelium, and v large vessels). (b) Rat lung ceramide (n= 3–5 rats/group; mean +SD. *p<0.05). (c–e) Mouse lung enzymatic activities of ceramide synthase (c, n=4/group, +SD, *p=0.02); soluble (secretory) and lysosomal ASMase at 3d (d, n=4/group, +SE, p=0.04); and neutral sphingomyelinase (e, n=4/group; mean +SD). (f) Lung ceramides and ceramide metabolites at 7d after VEGFR-inh (n=4) or Ctl (n=3); mean +SE, *p<0.05.